Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
3(33%)
Results Posted
0%(0 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_2
2
22%
Ph early_phase_1
1
11%
Ph phase_1
4
44%
Ph phase_3
2
22%

Phase Distribution

5

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

3

trials recruiting

Total Trials

9

all time

Status Distribution
Active(3)
Completed(5)
Terminated(1)

Detailed Status

Completed5
Recruiting3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
3
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (11.1%)
Phase 14 (44.4%)
Phase 22 (22.2%)
Phase 32 (22.2%)

Trials by Status

recruiting333%
terminated111%
completed556%

Recent Activity

3 active trials
Showing 5 of 9
recruitingphase_3

[18F]PI-2620 Phase 3 Histopathological Study

NCT05641688
recruitingphase_3

PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620

NCT05456503
recruitingphase_2

Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease

NCT07020026
completedphase_1

Test-retest Study With [18F]PI-2620 in PSP-RS and NDC

NCT05187546
completedphase_1

Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity

NCT04715750
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05641688Phase 3

[18F]PI-2620 Phase 3 Histopathological Study

Recruiting
NCT05456503Phase 3

PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620

Recruiting
NCT07020026Phase 2

Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease

Recruiting
NCT05187546Phase 1

Test-retest Study With [18F]PI-2620 in PSP-RS and NDC

Completed
NCT04715750Phase 1

Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity

Completed
NCT05337774Phase 1

Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury

Terminated
NCT03903211Phase 2

Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease

Completed
NCT04566003Phase 1

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

Completed
NCT03510572Early Phase 1

Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9